Global Digital Pathology Market, 2017 Companies-To-Action

Global Digital Pathology Market, 2017 Companies-To-Action

Collaborative Business Models Embracing Artificial Intelligence Application in Novel Disease Areas to Drive Market Growth

RELEASE DATE
31-Oct-2017
REGION
Global
Research Code: MD84-01-00-00-00
SKU: HC02915-GL-MR_21043
AvailableYesPDF Download

$3,000.00

Special Price $2,250.00 save 25 %

In stock
SKU
HC02915-GL-MR_21043

$3,000.00

$2,250.00save 25 %

DownloadLink
ENQUIRE NOW

Description

It is estimated that more than 19,000 pathologists would be needed to serve the US healthcare needs. However, the actual number is expected to be approximately 40% lesser. Similar trends are foreseen globally driven by aging population and widening application in areas such as cancer diagnostics, drug development, clinical trials, biomarker discovery, and companion diagnostics. Digital pathology can improve efficiency of pathologists by 10–15%, thereby helping the healthcare providers in filling such gaps. This factor is a key driver for the rapid growth in adoption of digital pathology solutions globally.

In April 2017, FDA approved the IntelliSite Pathology Solution from Royal Philips. This was the first digital pathology product for which any US manufacturer received approval for primary diagnostics purpose. An expected increase in regulatory approval for digital pathology systems for primary diagnostics will support the growth in demand for these systems.

To cater to the growing demand for digital pathology solutions, the industry has observed numerous partnerships, collaborations, and M&As. These strategies have been undertaken to expand product portfolio and deepen solution expertise while catering to changing customer demands.

Research Scope:
The key objectives of the companies-to-action for digital pathology study are to highlight current market dynamics, key market participants, customer segments, and evolving business opportunities. The study aims to identify both established enterprises and start-ups, which are capable of shaping the future through best practices implementation, visionary leadership, and innovation in business models.

Further, the study provides an analysis of companies segregated by hardware, software, services and storage. It covers business profile, key solution offerings, target customer segments, service differentiators, and future growth strategies.

The study also highlights growth opportunities, case study of notable market developments, key trends, mergers and acquisitions, for investment and collaboration opportunities.

Companies mentioned in the study are Agfa Healthcare, Corista, Definiens, Fimmic Oy, GE (Omnyx), Hamamatsu, Huron Digital Pathology, Indica Labs, Inspirata, Leica Biosystems, OptraSCAN, Pathcore, Philips, Proscia, Sectra, Sunquest, Visiopharm, Ventana Medical Systems, Roche, and 3D Histech.

Key questions this study will answer:
• How are digital pathology companies creating extraordinary value for stakeholders?
• Which are some unique companies that are introducing new and innovative solutions in the market?
• How do these companies intend to transform healthcare industry paradigms in the future? What is the impact of the external industry
environment on this market?
• What is their action plan and potential for growth?
• What are the current growth opportunities in digital pathology?
• What are some key success factors in the digital pathology market?
• Which are the companies with whom partnerships can be forged?

RESEARCH: INFOGRAPHIC

This infographic presents a brief overview of the research, and highlights the key topics discussed in it.
Click image to view it in full size

Table of Contents

Methodology

Scope and Segmentation

Key Findings

Companies-To-Action Value Creators

Threats & Opportunities

Definition and Solution Segmentation

Impact of Key Market Influencers

Top 3 Trends and Vendor Strategies

C2A Targets Aligned with Top 3 Trends

Value Chain Analysis

Benchmarking of Top Companies-To-Action

Corista

Definiens

Hamamatsu

Indica Labs

Inspirata

Leica Biosystems

OptraSCAN

Pathcore

Sectra

Ventana Medical Systems—Roche

3DHISTECH Ltd.

Short Profiles of Digital Pathology Companies (1 of 2)

Short Profiles of Digital Pathology Companies (2 of 2)

GE Healthcare and Omnyx—Case Study 1

GE Philips—Case Study 2

Key Mergers and Acquisitions

Top 5 Growth Opportunities

Strategic Imperatives for the Digital Pathology Market

Conclusion—Key Takeaway from the Companies-To-Action Analysis

Legal Disclaimer

Comparative Matrix of Companies

Interested in Full Access? Connect With Us

List of Figures
  • 1. Digital Pathology Market: Key Segments, Global, 2017
  • 2. Digital Pathology Market: Acquisitions and Partnerships by Philips, Global, 2015–2017
  • 3. Digital Pathology Market: Mergers and Acquisitions, Global, 2010–2016
  • 4. Digital Pathology Market: Solution Portfolio Comparative Matrix, Global, 2017
List of Charts
  • 1. Digital Pathology Market: Companies-To-Action Value Creators, Global, 2017
  • 2. Digital Pathology Market: Impact of Key Market Influencers, Global, 2017
  • 3. Digital Pathology Market: C2A Targets Aligned with Top 3 Trends, Global, 2017
  • 4. Digital Pathology Market: Value Chain Analysis, Global, 2017
  • 5. Digital Pathology Market: Companies-To-Action, Key Areas to Focus, Global, 2017
  • 6. Digital Pathology Market: GE Healthcare & Omnyx Joint Venture, Global, 2008–2016
Related Research
It is estimated that more than 19,000 pathologists would be needed to serve the US healthcare needs. However, the actual number is expected to be approximately 40% lesser. Similar trends are foreseen globally driven by aging population and widening application in areas such as cancer diagnostics, drug development, clinical trials, biomarker discovery, and companion diagnostics. Digital pathology can improve efficiency of pathologists by 10–15%, thereby helping the healthcare providers in filling such gaps. This factor is a key driver for the rapid growth in adoption of digital pathology solutions globally. In April 2017, FDA approved the IntelliSite Pathology Solution from Royal Philips. This was the first digital pathology product for which any US manufacturer received approval for primary diagnostics purpose. An expected increase in regulatory approval for digital pathology systems for primary diagnostics will support the growth in demand for these systems. To cater to the growing demand for digital pathology solutions, the industry has observed numerous partnerships, collaborations, and M&As. These strategies have been undertaken to expand product portfolio and deepen solution expertise while catering to changing customer demands. Research Scope: The key objectives of the companies-to-action for digital pathology study are to highlight current market dynamics, key market participants, customer segments, and evolving business opportunities. The study aims to identify both established enterprises and start-ups, which are capable of shaping the future through best practices implementation, visionary leadership, and innovation in business models. Further, the study provides an analysis of companies segregated by hardware, software, services and storage. It covers business profile, key solution offerings, target customer segments, service differentiators, and future growth strategies. The study also highlights growth opportunities, case study of notable market de
More Information
No Index No
Podcast No
Table of Contents | Executive Summary~ || Methodology~ || Scope and Segmentation~ || Key Findings~ | Companies-To-Action Overview~ || Companies-To-Action Value Creators~ || Threats & Opportunities~ | Digital Pathology Market Overview~ || Definition and Solution Segmentation~ || Impact of Key Market Influencers~ || Top 3 Trends and Vendor Strategies~ || C2A Targets Aligned with Top 3 Trends~ | Companies-To-Action Profiles~ || Value Chain Analysis~ || Benchmarking of Top Companies-To-Action~ || Corista~ || Definiens~ || Hamamatsu~ || Indica Labs~ || Inspirata~ || Leica Biosystems~ || OptraSCAN~ || Pathcore~ || Sectra~ || Ventana Medical Systems—Roche~ || 3DHISTECH Ltd.~ || Short Profiles of Digital Pathology Companies (1 of 2)~ || Short Profiles of Digital Pathology Companies (2 of 2)~ | Competitive Playbook~ || GE Healthcare and Omnyx—Case Study 1~ || GE Philips—Case Study 2~ || Key Mergers and Acquisitions~ | Growth Opportunities and Companies-to-Action~ || Top 5 Growth Opportunities~ || Strategic Imperatives for the Digital Pathology Market~ | The Last Word~ || Conclusion—Key Takeaway from the Companies-To-Action Analysis~ || Legal Disclaimer~ | Appendix~ || Comparative Matrix of Companies~ | The Frost & Sullivan Story~ || Interested in Full Access? Connect With Us~
List of Charts and Figures 1. Digital Pathology Market: Key Segments, Global, 2017~ 2. Digital Pathology Market: Acquisitions and Partnerships by Philips, Global, 2015–2017~ 3. Digital Pathology Market: Mergers and Acquisitions, Global, 2010–2016~ 4. Digital Pathology Market: Solution Portfolio Comparative Matrix, Global, 2017~| 1. Digital Pathology Market: Companies-To-Action Value Creators, Global, 2017~ 2. Digital Pathology Market: Impact of Key Market Influencers, Global, 2017~ 3. Digital Pathology Market: C2A Targets Aligned with Top 3 Trends, Global, 2017~ 4. Digital Pathology Market: Value Chain Analysis, Global, 2017~ 5. Digital Pathology Market: Companies-To-Action, Key Areas to Focus, Global, 2017~ 6. Digital Pathology Market: GE Healthcare & Omnyx Joint Venture, Global, 2008–2016~
Author Supratik Paul
Industries Healthcare
WIP Number MD84-01-00-00-00
Keyword 1 Digital Pathology
Keyword 2 Pathologists
Is Prebook No